Patrick Stang, MD
Psychiatry · Great Bend, KSNPI 1639100183
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,320 of the $27,779 with a category attached, or 76.7%. 15 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 56.8% of the total. Reporting peaked in 2019 at $10,140 and has fallen 95.4% since, to $466 in 2025. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $156.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$16K
- Otsuka America Pharmaceutical, Inc.$10K
- Alkermes, Inc.$315
- Neurocrine Biosciences, Inc.$313
- Johnson & Johnson$293
- AbbVie$222
- plus $852 from 9 others
What the payments were for
- Speaking & faculty fees$21,32077%
- Travel & lodging$3,43312%
- Food & beverage$3,02611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $15,777 |
| Otsuka America Pharmaceutical, Inc. | 41 | $10,006 |
| Alkermes, Inc. | 15 | $315 |
| Neurocrine Biosciences, Inc. | 18 | $313 |
| Johnson & Johnson | 14 | $293 |
| AbbVie | 13 | $222 |
| Teva Pharmaceuticals USA, Inc. | 10 | $212 |
| Vanda Pharmaceuticals Inc. | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $96 |
| Supernus Pharmaceuticals, Inc. | 5 | $84 |
| Corium, LLC | 3 | $72 |
| Axsome Therapeutics, Inc. | 3 | $62 |
| Lundbeck LLC | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,779 in reported general payments places this provider in the 95th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 40 | $144,726 |
| RexultiBrexpiprazole | 69 | $98,389 |
| VraylarCariprazine Hcl | 58 | $83,688 |
| Abilify MaintenaAripiprazole | 28 | $79,932 |
| AristadaAripiprazole Lauroxil | 11 | $34,381 |
| CaplytaLumateperone Tosylate | 16 | $27,464 |
| Paliperidone ErPaliperidone | 68 | $22,765 |
| ZyprexaOlanzapine | 14 | $22,020 |
| Atomoxetine Hcl | 93 | $18,736 |
| TrintellixVortioxetine Hydrobromide | 32 | $15,412 |
| Divalproex Sodium ErDivalproex Sodium | 68 | $13,722 |
| BelsomraSuvorexant | 30 | $13,018 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 43 | $9,197 |
| Lurasidone Hcl | 28 | $8,700 |
| Aripiprazole | 155 | $8,659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $10,006 | $178,32197 claims |
| Johnson & JohnsonInvega Sustenna | $293 | $144,72640 claims |
| AbbVieVraylar, Fetzima | $222 | $89,91271 claims |
| Alkermes, Inc.Aristada | $315 | $34,38111 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $15,777 | $27,46416 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $101 | $15,41232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Great Bend
- David WichmanManhattan$613K
- Kevin MaysLeawood$548K
- Sheldon PreskornWichita$498K
- James OwensSalina$433K
- Sasha HamdaniOverland Park$104K
- Christine GlennKansas City$58K
- Heidi OgdenWichita$55K
- Mark RomereimHays$41K
- Ralph BharatiWichita$26K
- Sonni ElliottLeawood$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.